AlphaMed Appoints Maureen Maher-Dominguez Marketing & Account Manager
AlphaMed Press has appointed Maureen Maher-Dominguez as Marketing and Account Manager for its print and online journals: The Oncologist®, Stem Cells®, and The Oncologist® CME Online.
Durham, NC (PRWEB) July 8, 2004
AlphaMed Press has appointed Maureen Maher-Dominguez as Marketing and Account Manager for its print and online journals: The Oncologist®, Stem Cells®, and The Oncologist® CME Online.
Maureen comes to AlphaMed Press from Torre Lazur Communications where she was VP, Account Supervisor in Oncology. Maureen began her career in the media department of Lyons Lavey Nickel Swift and subsequently was appointed Medical Media Director of Carrafiello Diehl & Associates. Maureen may be reached by phone (+845.461.8314) or via e-mail (MDominguez@TheOncologist. com).
About AlphaMed Press
AlphaMed Press publishes peer-reviewed medical and scientific journals, The Oncologist®, The Oncologist® CME Online, and Stem Cells® .
The Oncologist® was established a decade ago by internationally acclaimed oncologists to support physicians entrusted with cancer patient care. With a circulation of more 21,000, it ranks among the world’s most respected peer-reviewed cancer medicine journals with an impact factor of 3.962.
The Oncologist® CME Online offers peer-reviewed fair and balanced cancer medical educational programs for physicians. Co-sponsored by the National Institutes of Health, there are more than 200 category-1 hours of CME credits available online that cover all aspects of oncology including risk management.
Stem Cells® was established more than two decades ago and has helped to usher in this fast paced field. It covers all aspects of stem cell cells: embryonic and somatic stem cell biology; stem cell genetics and genomics; stem cell-microenvironment interactions; ex vivo expansion of hematopoietic and other tissue-specific stem cells; somatic stem cell transdifferentiation; translational research in tissue regeneration and gene therapies; molecular mechanisms of stem cell transformation in malignancy; and clinical applications. Its impact factor of 5.802 places it in the top five percent of cancer biology journals.
